Every Cure

We are thrilled to share that The @nytimes has just featured @EveryCure and our work using repurposed drugs to save lives. The article highlights how our AI-driven approach is identifying lifesaving treatments that were hiding in plain sight. It tells the powerful story of patient Joseph Coates, who at 37 years old was given just weeks to live due to a rare disease—until an AI-predicted treatment, helped save his life. This recognition is a testament to our mission: ensuring that every FDA-approved drug is fully utilized to treat every disease it possibly can. We are incredibly grateful for the opportunity to shed light on this critical work and the potential AI holds for revolutionizing medicine.  Click the link in our bio to read the full article! Photo credit: @hanloveyoon #EveryCure #DrugRepurposing #AIforGood #HealthcareInnovation #RareDisease #NYTimes

A few days ago, we learned that the first patient in the U.S., to our knowledge, has been dosed with lidocaine for their breast cancer treatment. Just six weeks ago, we learned about the potential connection between lidocaine and improved breast cancer outcomes from a groundbreaking clinical trial of 1,600 patients conducted in India. That study showed a potential 30% reduction in five-year mortality for patients who received lidocaine injections into their tumors before surgery. Since then, we’ve engaged in discussions  with specialists and researchers, and what we’ve discovered has been surprising —no one seemed to be using this approach, despite the data available. The other day, one of those conversations turned into action. A doctor we spoke to decided to inject a tumor with lidocaine before removing it, marking a critical first step toward translating global insights into real-world patient care. This moment excites us because it shows the power of accelerating drug repurposing insights into clinical practice. At Every Cure, this is exactly what drives us: identifying overlooked opportunities and ensuring they reach patients who need them most—quickly and efficiently. #medicine #DrugRepurposing #breastcancerawareness #breastcancersurvivor #BreastCancer

We’re excited to share that one of Every Cure’s drug repurposing programs has reached a major milestone. In a recent publication with Luke Chen in the Journal of Haematology, we report that 10 patients with Rosai-Dorfman disease—a rare and potentially life-threatening hyperinflammatory condition—experienced substantial improvement when treated with lenalidomide/dexamethasone. This program was identified through our MATRIX platform, where it ranked highly as a promising repurposing opportunity. It’s a powerful example of what happens when you systematically search for new uses for existing medicines—and find treatments that can be moved forward quickly to help patients. Rosai-Dorfman disease is incredibly rare and often overlooked. But this is exactly what Every Cure is built for—taking medicines that already exist and applying them to diseases that have long been neglected. Because for patients with rare diseases, the goal isn’t someday. It’s as soon as possible.

Colon cancer is rising and it’s becoming one of the most deadly cancers in young people. Just last week, a friend I grew up with was diagnosed. We’re hopeful he’ll respond well to treatment. But moments like this are a reminder that there are treatments available today that many patients still don’t hear about. Some of these are repurposed medicines. Drugs like pembrolizumab, which helped a close friend during her battle with colon cancer, and even something as accessible as aspirin, which has been shown to reduce recurrence in certain patients with specific mutations. These are not future breakthroughs. They are treatments that can help patients right now. The challenge is awareness. At @EveryCure , this is exactly what we’re working to change—making sure that life-saving treatments don’t stay hidden in the data, but reach the patients who need them. Share this. Because awareness could help someone get access to a treatment that already exists.

Here are three steps you can take when a doctor says, “There are no more treatments” 1. Contact the disease organization. They may know of clinical trials or off-label treatments already being used for your condition. 2. Push for expert outreach. Ask your doctor to connect with specialists across the country who may have insights. If needed, travel to a center of excellence—it could save a life. 3. Explore AI-driven predictions. Tools like TXGNN, the Biomedical Data Translator, and Open Evidence are beginning to surface new treatment possibilities. These predictions must always be discussed with your doctor, but they can spark life-saving options. At Every Cure, we’re committed to ensuring that no potentially life-saving treatment is left on the shelf. Our AI technology scans across thousands of FDA-approved drugs and tens of thousands of diseases to uncover hidden treatment opportunities—especially for conditions that have been overlooked or underfunded. But AI predictions are just the beginning. Once our platform identifies a promising match, our medical and scientific teams step in to validate those findings through rigorous lab studies and clinical trials. We know that patients and their families can’t afford to wait. That’s why our goal is not just to generate ideas—but to translate them into real treatments that reach the people who need them most.

Among more than 20,000 human diseases, how do you decide where to focus? At @everycure , we built an Unmet Medical Need Index to answer exactly that. It’s a data-driven way to evaluate how devastating each disease is—so when we identify promising drug repurposing opportunities, we can prioritize the ones with the potential to help patients who need it most. We hear from thousands of patients and organizations asking us to work on their disease. And the truth is, we want to help every one of them. This index helps us do that more effectively—by matching the right drugs to the diseases with the greatest unmet need, and making sure our efforts are directed where they can have the biggest impact. We’re excited to share that we recently published a paper outlining this approach and the methodology behind it, marking an important step toward making research prioritization more transparent and scalable. Because in a world with limited time and resources, prioritization isn’t about choosing some patients over others. It’s about finding the fastest path to help as many as possible.

Can we prioritize one disease over another and accelerate a cure on demand? It’s one of the most common questions we get. The reality is that Every Cure is built to look across all 18,000 diseases at once, systematically scoring thousands of drugs against each one. We are not yet in a position to focus exclusively on a single condition by request. Instead, we work through this massive landscape methodically, reviewing more than 1,000 opportunities every month to identify the most promising matches between existing drugs and diseases. What is powerful is the scale of this approach. There is a real chance we are already evaluating a potential treatment for the disease you care about. In many cases, the answer is not starting from scratch. It is uncovering something that may already exist and accelerating it forward with the right data, resources, and collaboration. This clip was recorded at the @peterdiamandis Abundance Summit. So grateful to be part of a community pushing the boundaries of what’s possible in healthcare and beyond.

“I was 22 years old when my body started to feel like it wasn’t mine anymore. At first, it was small things. Walking up a flight of stairs felt harder than it should. My body started to swell. I remember standing there with my dad thinking, something’s not right—but I couldn’t explain it. Over the next few weeks, everything got worse. I kept going to appointments, getting tests, waiting for answers—but no one could tell me what was happening. It felt like my body was slipping, and no one knew how to stop it. Eventually, I got so sick that I ended up in the hospital. That’s when things got real. My mom lives over 20 hours away in New Brunswick. When she heard how bad things were, she dropped everything. Two ferry rides. A ten-hour drive. She just needed to get to me. I don’t remember much from that time. But she does. She remembers sleeping in hospital hallways. She remembers me being scared. She told me later that I asked her to sing to me—like she used to when I was a kid. While I was in the hospital, she was searching for answers nonstop. Reading everything she could. Trying to piece things together. That’s when she came across something called Castleman disease. Around that same time, my doctor—Dr. Steven Rowe—was starting to think the same thing. I was diagnosed with idiopathic multicentric Castleman disease with TAFRO syndrome. A rare and aggressive disease where your immune system turns on your own body. Once they figured it out, everything changed. I started treatment with siltuximab. Slowly, my body began to stabilize. Today, I’m still on treatment. I go in for infusions every six weeks. But I’m living my life again. What I don’t remember, my mom carries with her. And now she’s using it to help other families—working to make sure doctors can recognize this disease sooner, so someone else doesn’t have to go through what we did. This disease didn’t just change my life. It changed ours.” -Ian G.

There is a massive gap in medicine that most people never see. It is not caused by a lack of scientific discovery or a shortage of promising drugs. It is caused by incentives. When a medicine becomes generic, companies lose the ability to profit from proving new uses for it. That means even if a low-cost drug could treat cancer, Alzheimer’s, or rare diseases, there is often no financial reason to run the clinical trial that would validate it. A recent economic analysis estimates that this missing innovation is worth between $2.5 and $10 trillion in lost value. Hundreds of potential treatments may already exist but remain unproven and unused because no one is incentivized to develop them. @everycure was built to change that by systematically identifying these opportunities and helping bring them to patients. Because we believe that no patient should suffer when there could be a potential treatment sitting on the pharmacy shelf.

What if a drug that’s been used for decades to treat bipolar disorder could also help slow memory decline? A new randomized clinical trial published in JAMA Neurology tested low-dose lithium in older adults with mild cognitive impairment for two years. The results suggested that people taking lithium experienced a slower rate of memory decline compared with those taking placebo. Importantly, the study also found that low-dose lithium was generally safe and tolerable in older adults, helping establish feasibility for larger trials. The results don’t prove lithium prevents the progression of dementia, but they add to growing evidence that this long-standing medication may influence biological pathways involved in Alzheimer’s disease and could be worth studying in larger clinical trials.

It was such an honor to sit down with @jujuchangabc at the @lakenonaimpactforum to discuss @everycure ’s mission and work! Four years ago at @lakenonaimpactforum is where I first shared about the dream that @grantwmitchell and I had for Every Cure and Lake Nona’s support helped us to turn that dream into a reality! That journey made this year’s moment even more meaningful. I was deeply honored to be recognized with the Impact Award and even more surprised when my family joined me on stage to celebrate the moment together. A huge thank you to the entire @lakenonaimpactforum community for believing in this vision from the very beginning. We’re doing everything in our power to advance our mission of saving and improving lives by repurposing drugs for patients who need them most.

“Doctors used to call it ‘the Jameson.’ They had never seen another child like him. They didn’t have a name for what was happening to his body — so before there was a diagnosis, it was just him. Jameson was born by emergency C-section at 38 weeks and spent his first month in the NICU. We did genetic testing. Then more testing. Exome sequencing. Still no answers. For years we lived in that in-between — knowing something wasn’t typical but not knowing what. When he was five, whole genome sequencing at Stanford finally gave us a diagnosis: Bachmann-Bupp syndrome (BABS). I remember Googling it and finding one story — a little girl named Marley. I reached out to her mom on Facebook, and through that connection we found Drs. Bachmann and Bupp. We started DFMO, a treatment that wasn’t originally made for Bachmann-Bupp syndrome but had shown hope with other kids like Jameson.  Within weeks, we saw hair regrowth. Then developmental progress. Slow, incremental improvements. More understanding. More communication. Jameson is now able to take independent walking steps. He’s in fifth grade now. He uses sign language, an AAC device, and some words — and he loves saying “hi” to everyone. He loves remote control cars, swinging, bike rides, and cruising the wide aisles at Lowe’s in his wheelchair like he owns the place. For the longest time, we thought we were alone. Now there’s a growing community of BABS families around the world supporting one another. Today is Rare Disease Day but we celebrate it all month long with a Rare Disease Day flag hanging in our home. Because every rare diagnosis deserves awareness. And every child — including ours — deserves a future full of possibility.” - Kayla J, Jameson’s mom